Vittamed Corporation, a Boston, MA-based neurodiagnostic company that has developed a novel non-invasive intracranial pressure monitor, secured $10M in Series A financing.
The round was led by Xeraya Capital Labuan Ltd via a special purpose vehicle ($8M committed) with participation from existing investor Imprimatur Capital and others.
The company intends to use the funds for product launch in Europe, Australia, and other countries, a 510k submission to the FDA, and commercialization in the US.
Led by CEO Dr. Remis Bistras, Vittamed is a commercial stage neurodiagnostic company which has developed a platform of innovative noninvasive devices:
– Vittamed 205 non-invasive intracranial pressure (ICP) system that does not require patient specific calibration; and
Vittamed 505 non-invasive bedside monitor for assessing cerebrovascular autoregulation.
Both devices have CE Mark approval.
The company has also research and manufacturing operations in Lithuania.